Skip Navigation LinksHome > August 2003 - Volume 99 - Issue 2 > Neuroprotective Effects of Propofol in a Model of Ischemic C...
Laboratory Investigations

Neuroprotective Effects of Propofol in a Model of Ischemic Cortical Cell Cultures: Role of Glutamate and Its Transporters

Velly, Lionel J. M.D.*; Guillet, Benjamin A. Ph.D.†; Masmejean, Frederique M.‡; Nieoullon, André L. Ph.D.§; Bruder, Nicolas J. M.D.∥; Gouin, François M. M.D.#; Pisano, Pascale M. Ph.D.**

Free Access
Article Outline
Collapse Box

Author Information

Collapse Box


Background: During cerebral ischemia, excess of glutamate release and dysfunction of its high affinity transport induce an accumulation of extracellular glutamate, which plays an important role in neuronal death. The authors studied the relationship among propofol neuroprotection, glutamate extracellular concentrations, and glutamate transporter activity in a model of ischemic cortical cell cultures.
Methods: Thirteen-day-old primary cortical neuronal-glial cultures were exposed to a 90-min combined oxygen–glucose deprivation (OGD) in an anaerobic chamber, followed by reoxygenation. Propofol was added only during the OGD period, and its effect was compared to that of the N-methyl-d-aspartate receptor antagonist dizocilpine (MK-801). Twenty-four hours after the injury, cell death was quantified by lactate dehydrogenase release and cell viability by reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT). Extracellular concentrations of glutamate in culture supernatants and glutamate uptake were performed at the end of OGD period by high-performance liquid chromatography and incorporation of l-[3H]glutamate into cells, respectively.
Results: At clinically relevant concentrations (0.05–10 μm), propofol offered protection equivalent to that of MK-801. It significantly reduced lactate dehydrogenase release and increased the reduction of MTT. At the end of the ischemic injury, propofol was able to reverse the OGD-induced increase in glutamate extracellular concentrations and decrease of glutamate uptake. The inhibition of the glial GLT1 transporter by 3-methyl-glutamate did not further modify the effect of propofol on glutamate uptake, suggesting that GLT1 was not the major target of propofol.
Conclusion: Propofol showed a neuroprotective effect in this in vitro model of OGD, which was apparently mediated by a GLT1-independent restoration of the glutamate uptake impaired during the injury.
PROPOFOL (2,6-diisopropylphenol), is widely used as an intravenous anesthetic. Recent experiments suggest that propofol can also enhance neurologic outcome and decrease the infarct size in animal models of stroke. 1–6In vitro attempts to clarify the ways in which propofol could interface with experimental ischemia still remain unclear. Several hypotheses have been considered, such as reduction in cerebral metabolism, 1 potentiation of γ-aminobutyric acid–mediated inhibition, 4 antioxidant activity, 6 or direct antiexcitotoxic properties. 7
Extracellular glutamate concentrations increase during ischemia, leading to excitotoxic neuronal death mainly due to overstimulation of glutamate N-methyl-d-aspartate (NMDA) receptors. 8 In physiologic conditions, the extracellular concentrations of glutamate depends on release into the synaptic cleft and uptake into cells by high-affinity glutamate transporters located both on neurons (EAAC1) and glial cells (GLAST and GLT1). The role of glutamate uptake during ischemia has been recently revisited in the way of an inhibition and even of an inversion of the glutamate transport, 9,10 thus allowing the neurotransmitter to be released from the nervous cells into the extracellular space. Extracellular glutamate concentration initially was not considered as a major determinant of the neuroprotective effect of propofol on in vivo models of ischemia. 11 However, it has been reported that propofol restored the glutamate uptake impaired by oxidative stress on cultured astrocytes, probably by scavenging free radicals formed during the injury. 12,13 So, a possible protective effect of propofol on glutamate transporter activity during ischemia is likely to occur and requires further study.
The aim of this study was first to quantify the putative neuroprotective effect of propofol on primary mixed cultures of neurons and astrocytes from rat cerebral cortex submitted to a transient oxygen–glucose deprivation (OGD). Such an experimental protocol was developed to reproduce, at least partly, the whole sequence of events occurring during ischemia and reperfusion. The noncompetitive NMDA receptor antagonist dizocilpine (MK-801) was used as the reference neuroprotectant. 14,15 Second, the putative involvement of the extracellular glutamate concentrations and glutamate uptake activity in the mechanism of the neuroprotective effect of propofol was explored.
Back to Top | Article Outline

Materials and Methods

The experimental protocols, involving animals and their care, strictly conformed to the guidelines of the French Agriculture and Forestry Ministry (decree 87-848, authorized researcher P. Pisano, authorization No. 1359, authorized Laboratory FRE 2131, Center National de la Recherche Scientifique, authorization No. A-13-457).
Back to Top | Article Outline
Preparation of Cell Cultures
Mixed cortical neuronal-glial cell cultures were prepared from cortex of 18-day-old Wistar rat fetuses. Briefly, after removal of meningeal, striatal, and hippocampal tissues and olfactory bulbs, cerebral cortices were pooled and maintained in ice-cold phosphate-buffered saline solution (PBS; Bio-Whittaker, Emerainville, France) supplemented with glucose (33 mm). Cells were mechanically dissociated from forebrains in dissociation medium by trituration through a fire-polished 9-in Pasteur pipette. After centrifugation (400 rpm for 10 min), the pellets were resuspended in Minimum Essential Media with Earle's salts, l-glutamine free (Life Technologies, Cergy-Pontoise, France), supplemented with 15 mm glucose (final concentration 20 mm), 5% fetal bovine serum, 5% horse serum (Sigma, Saint-Quentin Fallavier, France), 50 U/ml penicillin, and 50 μg/ml streptomycin and were plated to achieve a confluent monolayer (105 cells/cm2) on plastic 12-well culture plates (Costar, Brumath, France) previously coated with polyornithine (10 μg/ml). Culture dishes were incubated at 37°C in a humidified 6.0% CO2 and 94.0% air atmosphere. Experiments were performed on mature cultures, after synaptogenesis, in a serum-free medium, at 13 days in vitro. Cell types at 13 days in vitro were determined to be 66.9 ± 4.5% neurons, 20.3 ± 5.7% astrocytes, and 12.8 ± 2.7% undetermined cells, using immunochemical staining (see Immunochemistry section).
Back to Top | Article Outline
Oxygen–Glucose Deprivation followed by Reoxygenation
Mixed cultures were exposed to a transient OGD as described by Goldberg and Choi 16 with little modification. Cells were placed in an anaerobic chamber (partial pressure of oxygen [Po2] maintained at < 2 mmHg), and the medium was exchanged three times with a glucose-free balanced salt solution (BSS0–O2: 116 mm NaCl, 5.4 mm KCl, 0.8 mm MgSO4, 1.0 mm NaH2PO4, 1.8 mm CaCl2, 26.2 mm NaHCO3, 0.025 mm phenol red, 20 mm sucrose) bubbled with an anaerobic gas mix (95% N2, 5% CO2) for 30 min to remove residual oxygen. Cell cultures submitted to OGD were called control cells and were incubated in this solution at 37°C for a 90-min period to produce lethal oxygen deprivation. This OGD duration produced injury selectively limited to neurons, with no injury to the glial layer (see Results). Sham wash cell cultures, not submitted to OGD, were placed in BSS20–O2 containing 20 mm glucose and aerated for 10 min with an aerobic gas mix (95% air, 5% CO2). OGD was terminated by removing cultures from the chamber, replacing the exposure solution with oxygenated Minimum Essential Media supplemented with 20 mm glucose, and returning the multiwells to the incubator under normoxic conditions. Drugs (propofol, MK-801) were added at the start of OGD and were removed by washout during the reoxygenation process. Twenty-four hours after the injury, assessment of neuronal damage was qualitatively performed by phase-contrast microscopy and quantitatively by two biochemical tests measuring the release of cytoplasmic lactate dehydrogenase (LDH) and the reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and by counting of the immunolabeled neurons. Moreover, at the end of the OGD period, before reoxygenation, extracellular glutamate concentrations and glutamate uptake activity were determined.
Back to Top | Article Outline
Phase Contrast Microscopy
Neuronal injury was estimated by examination of cell morphology using a phase-contrast microscope at ×20, 24 h after the injury. A normal neuron was characterized by a soma with round and smooth shape, and processes that were uniform and smooth in appearance. Neurons were considered nonviable if they exhibited a rough appearance, irregular soma, or fragmented process.
Back to Top | Article Outline
LDH Release
Neuronal injury was quantitatively assessed by the measurement of LDH release into the bathing medium, immediately and 24 h after the OGD. This cytosolic enzyme is released from damaged or destroyed cells, and it has previously been established that LDH release correlates linearly with the number of damaged or dying neurons after both excitotoxic 17 and apoptotic injuries. 18 We used the Cytotoxicity Detection Kit (LDH) from Roche Diagnostic (Meylan, France). Background LDH concentrations (12%) were determined in sham wash sister cultures and subtracted from experimental values to yield the LDH activity specific to the experimental injury. Results obtained immediately and 24 h after the injury were pooled and expressed as percent of the maximal LDH concentration corresponding to a near complete neuronal death without glial cell death (= 100), determined by assaying sister cell cultures exposed to 300 μm NMDA and 1 μm glycine (Tocris; Fisher Bioblock Scientific, Illkirch, France) for a full 24 h.
Back to Top | Article Outline
MTT Reduction Test
Neuronal viability was quantitatively evaluated by the MTT reduction test. This quantifies the formation of a dark blue formazan product formed by the reduction of the tetrazolium ring of MTT by the mitochondrial succinate dehydrogenase in living cells. Twenty-four hours after exposure to OGD, cultures were incubated with MTT (250 μg/ml) at 37°C in culture medium for 3 h. Cultures were then washed and incubated in 0.08 N HCl/isopropanol to dissolve the blue formazan product. Cell viability corresponded to the value of the optical density read at 570 nm with background subtraction at 630 nm. Values obtained from cultures exposed to 300 μm NMDA and 1 μm glycine during the 24 h after the OGD (100% neuronal death) were subtracted from those measured in all experimental conditions. Results were expressed as percent of the optical density measured in sham wash cells.
Back to Top | Article Outline
To determine the number of astrocytes and neurons present in the culture, cells were plated on polyornithine-coated coverslips instead of 12-well plates and fixed, 24 h after the injury, with 4% (w/v) paraformaldehyde for 10 min. After washing with PBS, cells were preincubated (30 min at room temperature) in 18.3 mg/ml lysine (Sigma) and then for 10 min in PBS containing 3% (w/v) sheep serum (Sigma) and 0.1% (w/v) Triton X-100. For double immunochemical staining, cells were incubated (1 h at room temperature) using two primary antibodies. Neurons were labeled with mouse monoclonal antimicrotubule–associated protein (MAP2a; 1:450 dilution; Roche Diagnostics), and astrocytes were labeled with rabbit monoclonal antiglial fibrillary acidic protein (GFAP; 1:500 dilution; Dako, Trappes, France). Following extensive rinsing with PBS, coverslips were exposed for 1 h at room temperature to secondary antibodies from Molecular Probes (Interchim, Montluçon, France): Alexa Fluor 488 goat antirabbit immunoglobulin G (H+L) and Alexa Fluor 546 goat antimouse immunoglobulin G (H+L) diluted 1:250 in PBS containing 3% (w/v) sheep serum and 0.1% (w/v) Triton X-100. Nuclear counterstaining was performed with 4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI; 1:1,000 dilution; Sigma). Finally, the slides were mounted in Fluorsave (Calbiochem, Merck Eurolab, Strasbourg, France) before examination with a fluorescence microscope (Leica Microsystems, Marseille, France). The numeration was performed 24 h after the OGD exposure, with or without propofol. Results were expressed as percent of the total number of nuclei counterstained.
Back to Top | Article Outline
Measurement of Extracellular Amino Acids
Extracellular concentrations of glutamate in the culture supernatants were measured in duplicate at the end of the OGD period by high-performance liquid chromatography. An aliquot of 250 μl culture supernatant was deproteinized by 250 μl perchloric acid, 0.5 N, mixed and centrifuged (30,000 rpm for 10 min) at 4°C. The supernatant was then stored at −80°C until high-performance liquid chromatography analysis. All samples were analyzed for glutamate content using high-performance liquid chromatography along with a fluorometric detection (scanning fluorescence detector 474; Waters Corporation, Saint Quentin en Yvelines, France) after precolumn derivatization with o-phtaldialdehyde using a modified version of the method described by Geddes and Wood. 19 Each sample was diluted 1:20 in 0.15 m sodium borate buffer, and 10 μl of the dilution was directly injected into a C-18 column (5 μm Spherisorb; Richard Scientific, Novato, CA; ODS2 150 × 3 mm). The mobile phase consisted of 0.1 m potassium acetate (pH 5.8) in methanol (v/v, 1/7). Elution was performed with a methanol gradient ranging from 12.5 to 56%. Glutamate concentrations in the culture supernatants were calculated with reference to a standard mixture (Millenium32 version 3.05; Waters Corporation, Milford, MA). Results were expressed in micromolars.
Back to Top | Article Outline
Uptake Experiments
Uptake experiments were performed at the end of the injury on sham wash and on control cells, treated or untreated with propofol. In experiments performed to test the potential direct effect of propofol on basal glutamate uptake, the compound was added on sham wash cells 90 min before uptake measurements. After two washes of the cells with the uptake buffer (10 mm glucose, 5 mm KCl, 127 mm NaCl, 2.5 mm CaCl2, 0.2 mm MgSO4, 0.3 mm NaH2PO4, and 10 mm HEPES; pH 7.4), uptake assays were performed as previously described. 20 Briefly, the reaction started by adding l-[3H]glutamate (specific activity 15–25 Ci/mmol NEN, Paris, France) at 10−6 m final concentration, diluted in the buffered physiologic medium. Incubations were performed at 37°C for 2 min. The reaction was stopped by rapidly adding 1 ml cold, sodium-free buffer, followed by two washes with the same cold medium. To dissolve the cells, 1 N NaOH was added to the culture dishes, and the radioactivity was assessed by liquid scintillation counting at least 12 h later. To determine the part of radioactivity not due to sodium-dependent glutamate transport, l-[3H]glutamate uptake was assessed in physiologic medium in which sodium was omitted and replaced by choline. Glutamate transport was calculated as glutamate uptake rate in the presence of sodium minus glutamate uptake in the absence of sodium. Protein content was determined by the method developed by Lowry et al.21 with bovine serum albumin as the standard. To estimate the role of the glial glutamate transporter 1 (GLT1) in the measured uptake rates, some incubations were performed in the presence of threo-3-methyl glutamate (3-MG; Tocris; Fisher Bioblock Scientific), an inhibitor of this carrier, which was dissolved in water and added at the time of the uptake experiments. Results (pmol glutamate/mg protein/min) were expressed as percent of the value obtained in sham wash cells.
Back to Top | Article Outline
Statistical Analysis
Statistical analysis was performed for each parameter, investigated by one-way analysis of variance followed by post hoc Tukey test for multiple comparisons (SAS version 8.1; SAS Institute Inc., Cary, NC). Values are reported as mean ± SD. Differences were considered significant for P < 0.05.
Back to Top | Article Outline
2,6-Diisopropylphenol (pure propofol) was supplied by AstraZeneca (Rueil Malmaison, France) and was dissolved in dimethylsulfoxide shortly before application to obtain final concentrations of 0.005–10 μm in the culture medium. Propofol was added at the beginning of the OGD period, and final dimethylsulfoxide concentration never exceeded 0.1%. The vehicle control experiments were performed by using the same amounts of dimethylsulfoxide and showed that the vehicle alone had no effect on the activities measured (data not shown). Dizocilpine maleate (MK-801; Tocris; Fisher Bioblock Scientific) a powerful noncompetitive NMDA glutamate receptor antagonist, was dissolved in water and added at 10 μm final concentration to the culture medium in a similar fashion to propofol for each experiment. Threo-3-methyl glutamate, a relatively specific inhibitor of the glial glutamate transporter GLT1, 22 was dissolved in water and added at 300 μm final concentration in the uptake medium.
Back to Top | Article Outline


Protective Effects of Propofol against OGD-induced Neuronal Injury
Fig. 1
Fig. 1
Image Tools
Neuronal damage was first assessed by light microscopic observations of either sham wash cells (fig. 1, Aa) or oxygen-glucose–deprived cells 24 h after a 90-min injury (fig. 1, Ab). As soon as the cells were removed from the anaerobic chamber, an osmotic swelling of the cell bodies was observed, followed by their shrinkage and disintegration of processes or irregular borders cell bodies, during the first hours after the reoxygenation. Finally, OGD elicited marked cell injury and accumulation of cellular debris 24 h after the injury (fig. 1, Ab). Propofol, 10 μm, added only during the OGD period, seemed to be a potent neuroprotective agent, as assessed by the conservation of the number of viable cells (fig. 1, Ac). Similar antiischemic effects were observed in the wells treated with 10 μm MK-801 (fig. 1, Ad).
Table 1
Table 1
Image Tools
These results were confirmed by cell counting after immunostaining experiments (table 1). Compared to sham wash cultures (fig. 1, Ba), the 90-min OGD exposure induced a significant 83% decrease of the neuronal count (MAP2a-positive cells) observed in control cultures (fig. 1, Bb). This decrease was partially but significantly reversed by propofol (fig. 1, Bc) and MK-801 (fig. 1, Bd). However, 10 μm MK-801 was of significantly less potency than the same concentration of propofol (table 1). The number of underlying glial cells (GFAP-positive cells) was not affected by the 90-min OGD, but the morphologic characteristics of the GFAP-labeled astrocytes shifted from a stellar to a flat configuration (fig. 1, Bb).
Fig. 2
Fig. 2
Image Tools
Lactate dehydrogenase release and MTT reduction are closely correlated with both morphologic assessment and cell counting for quantification of neuronal death. In fact, 24 h after the cortical neuronal-glial cell cultures were subjected to a 90-min OGD, 90.4 ± 0.9% of the neurons died as assessed by LDH release (fig. 2, A), and 15.8 ± 5.9% remained viable as estimated by MTT reduction (fig. 2, B). Propofol (0.05–10 μm) elicited a potent neuroprotective effect assessed by a significant reversion of the increase in LDH release and the decrease of the mitochondrial respiration both induced by OGD. The maximal neuroprotection was afforded by 10 μm propofol and was quite similar when estimated by LDH release (83%) or MTT reduction (81%). The reference neuroprotectant MK-801 (10 μm) also mitigated the effects of OGD on LDH release and MTT reduction but was significantly less potent than the same concentration of propofol on LDH efflux.
Back to Top | Article Outline
Propofol Inhibited the OGD-evoked Increase of the Glutamate Extracellular Concentration
Fig. 3
Fig. 3
Image Tools
At the end of the 90-min OGD exposure, before reoxygenation, glutamate extracellular concentrations were significantly increased compared to those measured in sham wash cells (fig. 3; control: 17.5 ± 5.4 μm vs. sham wash: 1.3 ± 0.8 μm). Propofol (10 μm) did not modify the glutamate extracellular concentration in sham wash cells. However, when propofol (concentrations at least equal to 0.05 μm) was added during the injury, it counteracted the OGD-induced elevation of glutamate concentrations. Moreover, propofol (0.5–10 μm) brought the extracellular glutamate concentration to sham wash amounts.
Back to Top | Article Outline
Propofol Partially Restored the Excitatory Amino Acid Uptake Rate after OGD Exposure: Role of Pharmacological Blockade of GLT1
Fig. 4
Fig. 4
Image Tools
Fig. 5
Fig. 5
Image Tools
At the end of the 90-min OGD, before reoxygenation, we observed a 40.6 ± 13.3% impairment of the l-[3H]glutamate uptake compared to the transport activity measured in sham wash cells (fig. 4). Propofol did not exhibit any effect on basal excitatory amino acid uptake rate measured on sham wash cells. However, after the OGD, propofol (0.005–10 μm) counteracted in a dose-dependent fashion the OGD-induced decrease of the apparent glutamate uptake rate. Moreover, 10 μm propofol maintained the glutamate uptake rate at the level measured in sham wash cells. To clarify the involvement of the glial glutamate transporter GLT1 in the uptake activity measured at the end of OGD with or without propofol, experiments were also performed in the presence of 300 μm 3-MG, which preferentially inhibits this carrier (fig. 5). 3-MG induced a 42.4 ± 14.1% decrease of the glutamate uptake rate measured in sham wash cells but did not further affect this activity after a 90-min OGD exposure (percent sham wash; control: 59.4 ± 13.3 vs. OGD + 3-MG: 53.4 ± 10.3). Another GLT1 inhibitor, dihydrokainate (500 μm), exhibited the same effects (data not shown). Moreover, the glutamate uptake rate measured in OGD cells treated with 0.5 μm propofol did not differ significantly in the presence or in the absence of 3-MG.
Back to Top | Article Outline


The neuroprotective effect of propofol on in vivo models of focal 1–5 or global 6,23,24 ischemia seem to be well established. Numerous in vitro studies have attempted to elucidate the mechanisms of this propofol-mediated neuroprotection, but most of the experiments were performed on models that only mimicked some of the damage observed during ischemia such as NMDA toxicity 25,26 or oxidative stress on cultured rat cortical astrocytes. 12,13
In this study, using a transient OGD on primary mixed cultures of neurons and astrocytes from rat cerebral cortex, we have shown that propofol partially reversed the OGD-induced neuronal death 24 h after the injury, as well as the increase in extracellular glutamate concentrations and the decrease of glutamate uptake activity both observed at the end of the ischemic injury. Moreover, we also reported that the glial glutamate transporter GLT1 did not seem to be a major target site for the protective effect of propofol.
The propofol concentrations used were chosen to be as close as possible to the concentrations of free propofol measured in the extracellular fluid of the somatosensory cortex in rats anesthetized with propofol (1 μm), 27 and to the propofol concentrations which scavenged peroxynitrite in human hepatic microsomes (2 μm). 28
Propofol exhibited a protective effect at least as important as that observed with MK-801 used as a reference against OGD-induced neuronal loss. In our model, the bulk neuroprotective effect of MK-801 against the experimental ischemic injury was due to the blockade of NMDA receptors and suggested a major role for excitotoxic mechanisms and especially for NMDA receptor activation in neuronal death. However, the effect of propofol on NMDA-mediated toxicity is still under debate. Propofol at high concentrations (IC50 = 160 μm) induced an allosteric inhibition of NMDA receptors 29 and protected cultured hippocampal neurons against NMDA neurotoxicity. 7 On the other hand, propofol exhibited either a lack of protection against NMDA excitotoxicity 25 in primary brain cell cultures or a worsening of the NMDA-induced neuronal damage on hippocampal slices. 26 Thus, an NMDA receptor–mediated neuroprotective effect of propofol could not be ruled out, but this did not seem to be the main mechanism of its antiischemic properties.
Other indirect antiexcitotoxic mechanisms could be involved in the neuroprotective effects of propofol during ischemia, such as the inhibition of the efflux of glutamate. Accumulation of glutamate in the extracellular space after in vivo or in vitro experimental ischemia is now a well-known phenomenon 30 depending on an excessive release 8 coupled to a decreased 10,31 or reversed 9 glutamate uptake process. At the end of the 90-min injury, we also described an OGD-induced increase in extracellular glutamate concentrations, which was similar to that observed in in vivo8 and in vitro32 models of cerebral ischemia. We reported here that propofol, although lacking an effect on basal extracellular glutamate concentrations in sham wash cells, counteracted the OGD-induced increase in extracellular glutamate concentrations. This effect is probably not due to the inhibition of glutamate release because Bickler et al.33 reported a lack of effect of propofol on hypoxia-evoked glutamate release on cortical brain slices. The maintenance of nonexcitotoxic glutamate concentrations during ischemic conditions in the presence of propofol could be due to a decrease of glutamate release dependent on presynaptic depolarization 34 or on oxidative stress–induced astrocytic efflux 13 but did not seem to be related to an effect on the reversal of the glutamate uptake process. 33 We rather suggested that propofol could lower extracellular glutamate concentrations after OGD at least in part via a drug-induced preservation of the glutamate transport activity. Propofol was inactive by itself on the glutamate uptake rate of the sham wash cultures in normoxic conditions. This lack of effect of propofol on glutamate uptake has also been described on synaptosomes from various rat brain regions 35 and on cultured astrocytes. 12,13 However, we reported here for the first time that, at clinically relevant concentrations, propofol curtailed the glutamate uptake rate inhibition in cultures exposed to OGD. This protective effect of propofol on the glutamate uptake may be due to several phenomenons. First, reactive oxygen species, formed during and after ischemia, may induce an inhibition of the glutamate uptake either directly by oxidation of the sulfhydryl groups of the glutamate carriers 36 or indirectly via the acidification of intracellular pH 37 due to the sodium-hydrogen exchanger oxidation. 38 Propofol's specific structure, including a phenolic hydroxyl group, confers free radical scavenging 39–41 and therefore antioxidant properties 42 leading to the protection of glutamate transporters 12,13 and sodium-hydrogen exchanger 38 after oxidative injury of primary astrocytes cultures by ter-butyl-hydroperoxide. So, in a similar fashion, in our in vitro model of OGD, propofol may limit the OGD-induced impairment of glutamate uptake via its antioxidant properties.
Second, another possibility could be that propofol may protect the transport activity via protein kinase C activation. 43 We have previously shown that this kinase up-regulated the glutamate uptake rates on synaptosomes and nervous cell cultures. 20,44 Do et al.45 also reported that the propofol-mediated enhancement of the activity of the neuronal glutamate transporter EAAC1 in Xenopus oocytes required the activation of protein kinase C.
Whatever the mechanism involved in the propofol-mediated protection of the glutamate transporters during OGD, the residual transport activity measured in control cells treated by this drug did not seem to reflect a GLT1-dependent process, since 3-MG, a rather specific GLT1 inhibitor, did not further inhibit glutamate uptake during OGD. However, 3-MG was able to dramatically reduce the uptake rate of the sham wash cells, indicating that the glutamate transport process in our normoxic experimental conditions relied for a great part on GLT1. The fact that 3-MG did not further decrease the glutamate transport activity during OGD may suggest that the GLT1-mediated glutamate uptake was totally inhibited by ischemic conditions. Similar findings have been reported during ischemia on hippocampal slices in the presence of dihydrokainate, 46 another specific GLT1 blocker. 47 Moreover, the effect of propofol on the glutamate uptake during OGD was not affected by 3-MG, indicating that propofol protected a transport mechanism which probably relied on glutamate transporters other than GLT1—the glial glutamate aspartate transporter or the neuronal excitatory amino acid carrier 1, both expressed in our experimental conditions. 48
In conclusion, this study confirmed a neuroprotective effect of propofol, at clinically relevant concentrations, in an in vitro model of OGD. It could be assumed that this beneficial effect of propofol on neuronal viability is mediated, at least in part, by a restoration of the glutamate transport activity, which is dramatically impaired by the OGD, thus allowing extracellular glutamate concentrations to be maintained below excitotoxic concentrations. Finally, our results also indicate that propofol protects a GLT1-independent transport mechanism, which could be mediated by the glial glutamate aspartate transporter or the neuronal excitatory amino acid carrier 1. Further research is needed to clarify the mechanism of the effect of propofol on glutamate transporter activity (increase in the number of membrane transporters or increase in the affinity of the transporters for glutamate).
Back to Top | Article Outline


1. Kochs E, Hoffman WE, Werner C, Thomas C, Albrecht RF, Schulte am Esch J: The effects of propofol on brain electrical activity, neurologic outcome, and neuronal damage following incomplete ischemia in rats. A nesthesiology 1992; 76: 245–52

2. Young Y, Menon DK, Tisavipat N, Matta BF, Jones JG: Propofol neuroprotection in a rat model of ischaemia reperfusion injury. Eur J Anaesthesiol 1997; 14: 320–6

3. Yamasaki T, Nakakimura K, Matsumoto M, Xiong L, Ishikawa T, Sakabe T: Effects of graded suppression of the EEG with propofol on the neurological outcome following incomplete cerebral ischaemia in rats. Eur J Anaesthesiol 1999; 16: 320–9

4. Ito H, Watanabe Y, Isshiki A, Uchino H: Neuroprotective properties of propofol and midazolam, but not pentobarbital, on neuronal damage induced by forebrain ischemia, based on the GABAA receptors. Acta Anaesthesiol Scand 1999; 43: 153–62

5. Gelb AW, Bayona NA, Wilson JX, Cechetto DF: Propofol anesthesia compared to awake reduces infarct size in rats. A nesthesiology 2002; 96: 1183–90

6. Ergun R, Akdemir G, Sen S, Tasci A, Ergungor F: Neuroprotective effects of propofol following global cerebral ischemia in rats. Neurosurg Rev 2002; 25: 95–8

7. Hans P, Bonhomme V, Collette J, Albert A, Moonen G: Propofol protects cultured rat hippocampal neurons against N-methyl-D-aspartate receptor-mediated glutamate toxicity. J Neurosurg Anesthesiol 1994; 6: 249–53

8. Benveniste H, Drejer J, Schousboe A, Diemer NH: Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984; 43: 1369–74

9. Rossi DJ, Oshima T, Attwell D: Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature 2000; 403: 316–20

10. Jabaudon D, Scanziani M, Gähwiler BH, Gerber U: Acute decrease in net glutamate uptake during energy deprivation. PNAS 2000; 97: 5610–5

11. Yano T, Nakayama R, Ushijima K: Intracerebroventricular propofol is neuroprotective against transient global ischemia in rats: Extracellular glutamate level is not a major determinant. Brain Res 2000; 883: 69–76

12. Sitar SM, Hanifi-Moghaddam P, Gelb AW, Cechetto DF, Siushansian R, Wilson JX: Propofol prevents peroxide-induced inhibition of glutamate transport in cultured astrocytes. A nesthesiology 1999; 90: 1446–53

13. Peters CE, Korcok J, Gelb AW, Wilson JX: Anesthetic concentrations of propofol protect against oxidative stress in primary astrocyte cultures: Comparison with hypothermia. A nesthesiology 2001; 94: 313–21

14. Church J, Zeman S, Lodge D: The neuroprotective action of ketamine and MK-801 after transient cerebral ischemia in rats. A nesthesiology 1988; 69: 702–9

15. Huang HM, Shen CC, Ou HC, Yu JY, Chen HL, Kuo JS, Hsieh SJ: Neuroprotective MK801 is associated with nitric oxide synthase during hypoxia/reoxygenation in rat cortical cell cultures. J Cell Biochem 2002; 84: 367–76

16. Goldberg MP, Choi DW: Combined oxygen and glucose deprivation in cortical cell culture: Calcium-dependent and calcium-independent mechanisms of neuronal injury. J Neurosci 1993; 13: 3510–24

17. Koh JY, Choi DW: Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods 1987; 20: 83–90

18. Gwag BJ, Lobner D, Koh JY, Wie MB, Choi DW: Blockade of glutamate receptors unmasks neuronal apoptosis after oxygen-glucose deprivation in vitro. Neuroscience 1995; 68: 615–9

19. Geddes JW, Wood JD: Changes in the amino acid content of nerve endings (synaptosomes) induced by drugs that alter the metabolism of glutamate and gamma-aminobutyric acid. J Neurochem 1984; 42: 16–24

20. Lortet S, Samuel D, Had-Aissouni L, Masmejean F, Kerkerian-Le Goff L, Pisano P: Effects of PKA and PKC modulators on high affinity glutamate uptake in primary neuronal cell cultures from rat cerebral cortex. Neuropharmacology 1999; 38: 395–402

21. Lowry OH, Rosebrough NJ, Far AR, Randall RJ: Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 247–54

22. Armer RE: Inhibitors of mammalian central nervous system selective amino acid transporters. Curr Med Chem 2000; 7: 199–209

23. Arcadi FA, Rapisarda A, De Luca R, Trimarchi GR, Costa G: Effect of 2,6-diisoprophylphenol on the delayed hippocampal cell loss following transient forebrain ischemia in the gerbil. Life Sci 1996; 58: 961–70

24. Yamaguchi S, Midorikawa Y, Okuda Y, Kitajima T: Propofol prevents delayed neuronal death following transient forebrain ischemia in gerbils. Can J Anaesth 1999; 46: 593–8

25. Shibuta S, Sriranganathan V, Inoue T, Shimizu T, Tomi K, Mashimo T: The effects of propofol on NMDA- or nitric oxide-mediated neurotoxicity in vitro. Neuroreport 2001; 12: 295–8

26. Zhu H, Cottrell JE, Kass IS: The effect of thiopental and propofol on NMDA- and AMPA-mediated glutamate excitotoxicity. A nesthesiology 1997; 87: 944–51

27. Shyr MH, Tsai TH, Tan PP, Chen CF, Chan SH: Concentration and regional distribution of propofol in brain and spinal cord during propofol anesthesia in the rat. Neurosci Lett 1995; 184: 212–5

28. Bao YP, Williamson G, Tew D, Plumb GW, Lambert N, Jones JG, Menon DK: Antioxidant effects of propofol in human hepatic microsomes: Concentration effects and clinical relevance. Br J Anaesth 1998; 81: 584–9

29. Orser BA, Bertlik M, Wang LY, MacDonald JF: Inhibition by propofol (2,6 di-isopropylphenol) of the N-methyl-D-aspartate subtype of glutamate receptor in cultured hippocampal neurones. Br J Pharmacol 1995; 116: 1761–8

30. Lipton P: Ischemic cell death in brain neurons. Physiol Rev 1999; 79: 1431–568

31. Bruhn T, Christensen T, Diemer NH: In vivo cellular uptake of glutamate is impaired in the rat hippocampus during and after transient cerebral ischemia: A microdialysis extraction study. J Neurosci Res 2001; 66: 1118–26

32. Kimura M, Sawada K, Miyagawa T, Kuwada M, Katayama K, Nishizawa Y: Role of glutamate receptors and voltage-dependent calcium and sodium channels in the extracellular glutamate/aspartate accumulation and subsequent neuronal injury induced by oxygen/glucose deprivation in cultured hippocampal neurons. J Pharmacol Exp Ther 1998; 285: 178–85

33. Bickler PE, Buck LT, Feiner JR: Volatile and intravenous anesthetics decrease glutamate release from cortical brain slices during anoxia. A nesthesiology 1995; 83: 1233–40

34. Ratnakumari L, Birch ML, Hemmings HC Jr: Widespread inhibition of sodium channel-dependent glutamate release from isolated nerve terminals by isoflurane and propofol. A nesthesiology 2001; 95: 1460–6

35. Nicol B, Rowbotham DJ, Lambert DG: Glutamate uptake is not a major target site for anaesthetic agents. Br J Anaesth 1995; 75: 61–5

36. Trotti D, Danbolt NC, Volterra A: Glutamate transporters are oxidant-vulnerable: A molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharmacol Sci 1998; 19: 328–34

37. Swanson RA, Farrell K, Simon RP: Acidosis causes failure of astrocyte glutamate uptake during hypoxia. J Cereb Blood Flow Metab 1995; 15: 417–24

38. Daskalopoulos R, Korcok J, Farhangkhgoee P, Karmazyn M, Gelb AW, Wilson JX: Propofol protection of sodium-hydrogen exchange activity sustains glutamate uptake during oxidative stress. Anesth Analg 2001; 93: 1199–204

39. Mouithys-Mickalad A, Hans P, Deby-Dupont G, Hoebeke M, Deby C, Lamy M: Propofol reacts with peroxynitrite to form a phenoxyl radical: Demonstration by electron spin resonance. Biochem Biophys Res Commun 1998; 249: 833–7

40. Demiryurek AT, Cinel I, Kahraman S, Tecder-Unal M, Gogus N, Aypar U, Kanzik I: Propofol and intralipid interact with reactive oxygen species: A chemiluminescence study. Br J Anaesth 1998; 80: 649–54

41. Green TR, Bennett SR, Nelson VM: Specificity and properties of propofol as an antioxidant free radical scavenger. Toxicol Appl Pharmacol 1994; 129: 163–9

42. Wilson JX, Gelb AW: Free radicals, antioxidants, and neurologic injury: Possible relationship to cerebral protection by anesthetics. J Neurosurg Anesthesiol 2002; 14: 66–79

43. Hemmings HC Jr, Adamo AI: Effects of halothane and propofol on purified brain protein kinase C activation. A nesthesiology 1994; 81: 147–55

44. Pisano P, Samuel D, Nieoullon A, Kerkerian-Le Goff L: Activation of the adenylate cyclase-dependent protein kinase pathway increases high affinity glutamate uptake into rat striatal synaptosomes. Neuropharmacology 1996; 35: 541–7

45. Do SH, Zuo Z: Effects of propofol on glutamate transporter, EAAC1: Role of protein kinase C (abstract). A nesthesiology 2002; 96: A734

46. Roettger V, Lipton P: Mechanism of glutamate release from rat hippocampal slices during in vitro ischemia. Neuroscience 1996; 75: 677–85

47. Arriza JL, Fairman WA, Wadiche JI, Murdoch GH, Kavanaugh MP, Amara SG: Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 1994; 14: 5559–69

48. Guillet B, Lortet S, Masmejean F, Samuel D, Nieoullon A, Pisano P: Developmental expression and activity of high affinity glutamate transporters in rat cortical primary cultures. Neurochem Int 2002; 40: 661–71

Cited By:

This article has been cited 38 time(s).

European Review for Medical and Pharmacological Sciences
Propofol inhibits invasion and enhances paclitaxel-induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug
Wang, P; Chen, J; Mu, LH; Du, QH; Niu, XH; Zhang, MY
European Review for Medical and Pharmacological Sciences, 17(): 1722-1729.

World Journal of Gastroenterology
Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of nuclear factor-kappa B activity
Du, QH; Xu, YB; Zhang, MY; Yun, P; He, CY
World Journal of Gastroenterology, 19(): 5485-5492.
Journal of Cerebral Blood Flow and Metabolism
Actin redistribution underlies the sparing effect of mild hypothermia on dendritic spine morphology after in vitro ischemia
Gisselsson, LL; Matus, A; Wieloch, T
Journal of Cerebral Blood Flow and Metabolism, 25(): 1346-1355.
A moderate dose of propofol and rapidly induced mild hypothermia with extracorporeal lung and heart assist (ECLHA) improve the neurological outcome after prolonged cardiac arrest in dogs
Ichinose, K; Okamoto, T; Tanimoto, H; Taguchi, H; Tashiro, M; Sugita, M; Takeya, M; Terasaki, H
Resuscitation, 70(2): 275-284.
European Journal of Pharmacology
Propofol reverses oxidative stress-attenuated glutamate transporter EAAT3 activity: Evidence of protein kinase C involvement
Yun, JY; Park, KS; Kim, JH; Do, SH; Zuo, ZY
European Journal of Pharmacology, 565(): 83-88.
Brain Research
Neuroprotective effect of propofol on necrosis and apoptosis following oxygen-glucose deprivation - Relationship between mitochondrial membrane potential and mode of death
Iijima, T; Mishima, T; Akayawa, K; Huaa, Y
Brain Research, 1099(): 25-32.
CNS Drug Reviews
Neuroprotective effects of propofol in acute cerebral injury
Adembri, C; Venturi, L; Pellegrini-Giampietro, DE
CNS Drug Reviews, 13(3): 333-351.

Neuroprotective effects of tacrolimus (FK506) in a model of ischemic coritcal cell cultures: Role of glutamate uptake and FK506 binding protein 12 kDa
Labrande, C; Velly, L; Canolle, B; Guillet, B; Masmejean, F; Nieoullon, A; Pisano, P
Neuroscience, 137(1): 231-239.
Developmental Brain Research
Loss of glial glutamate transporters and induction of neuronal expression of GLT-1B in the hypoxic neonatal pig brain
Pow, DV; Naidoo, T; Lingwood, BE; Healy, GN; Williams, SM; Sullivan, RKP; O'Driscoll, S; Colditz, PB
Developmental Brain Research, 153(1): 1-11.
Critical Care
Propofol: neuroprotection in an in vitro model of traumatic brain injury
Rossaint, J; Rossaint, R; Weis, J; Fries, M; Rex, S; Coburn, M
Critical Care, 13(2): -.
Folia Neuropathologica
The effect of propofol on astro- and microglial reactivity in the course of experimental intracerebral haemorrhage in rats
Karwacki, Z; Kowianski, P; Dziewiatkowski, J; Domaradzka-Pytel, B; Ludkiewicz, B; Wojcik, S; Narkiewicz, O; Morys, J
Folia Neuropathologica, 44(1): 50-58.

Taurine 6
Anti-neurotoxic effects of tauropyrone, a taurine analogue
Klusa, V; Klimaviciusa, L; Duburs, G; Poikans, J; Zharkovsky, A
Taurine 6, 583(): 499-508.

Neurochemical Research
Cerebellar granule neurons are more vulnerable to transient transport-mediated glutamate release than to glutamate uptake blockade. Correlation with excitatory amino acids levels
Estrada-Sanchez, AM; Camacho, A; Montiel, T; Massieu, L
Neurochemical Research, 32(3): 423-432.
Neurobiological Studies - From Genes to Behaviour 2006
Inhalational and intravenous anesthetics-Neuroprotectants or neurotoxins
Jevtovic-Todorovic, V
Neurobiological Studies - From Genes to Behaviour 2006, (): 55-70.

Anesthesia and Analgesia
Early Anesthetic Preconditioning in Mixed Cortical Neuronal-Glial Cell Cultures Subjected to Oxygen-Glucose Deprivation: The Role of Adenosine Triphosphate Dependent Potassium Channels and Reactive Oxygen Species in Sevoflurane-Induced Neuroprotection
Velly, LJ; Canas, PT; Guillet, BA; Labrande, CN; Masmejean, FM; Nieoullon, AL; Gouin, FM; Bruder, NJ; Pisano, PS
Anesthesia and Analgesia, 108(3): 955-963.
Anesthesia and Analgesia
Propofol Inhibits Aquaporin 4 Expression Through a Protein Kinase C-Dependent Pathway in an Astrocyte Model of Cerebral Ischemia/Reoxygenation
Zhu, SM; Xiong, XX; Zheng, YY; Pan, CF
Anesthesia and Analgesia, 109(5): 1493-1499.
Neural Regeneration Research
Effect of HX0507, a water-soluble propofol pro-drug, on subarachnoid hemorrhage-induced cerebral vasospasm in rabbits
Xue, XS; Zhu, T; Zhang, WS; Kang, Y; Liu, J
Neural Regeneration Research, 4(): 890-895.
Acta Anaesthesiologica Scandinavica
Treatment of elevated intracranial pressure with indomethacin: Friend or foe?
Rasmussen, M
Acta Anaesthesiologica Scandinavica, 49(3): 341-350.
Psychiatry Research
Changes in plasma amino acids after electroconvulsive therapy of depressed patients
Palmio, J; Huuhka, M; Saransaari, P; Oja, SS; Peltola, J; Leinonen, E; Suhonen, J; Keranen, T
Psychiatry Research, 137(3): 183-190.
Febs Letters
The intravenous anesthetic propofol inhibits hypoxia-inducible factor 1 activity in an oxygen tension-dependent manner
Takabuchi, S; Hirota, K; Nishi, K; Oda, S; Oda, T; Shingu, K; Takabayashi, A; Adachi, T; Semenza, GL; Fukuda, K
Febs Letters, 577(3): 434-438.

Neurochemistry International
Differential regulation by protein kinases of activity and cell surface expression of glutamate transporters in neuron-enriched cultures
Guillet, BA; Velly, LJ; Canolle, B; Masmejean, FM; Nieoullon, AL; Pisano, P
Neurochemistry International, 46(4): 337-346.
Neuroscience Letters
NMDA receptor mediated dendritic plasticity in cortical cultures after oxygen-glucose deprivation
Lei, ZG; Ruan, YW; Yang, AN; Xu, ZC
Neuroscience Letters, 407(3): 224-229.
CNS Neuroscience & Therapeutics
The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties
Kotani, Y; Shimazawa, M; Yoshimura, S; Iwama, T; Hara, H
CNS Neuroscience & Therapeutics, 14(2): 95-106.
Journal of Neurochemistry
ABCA2 is a marker of neural progenitors and neuronal subsets in the adult rodent brain
Broccardo, C; Nieoullon, V; Amin, R; Masmejean, F; Carta, S; Tassi, S; Pophillat, M; Rubartelli, A; Pierres, M; Rougon, G; Nieoullon, A; Chazal, G; Chimini, G
Journal of Neurochemistry, 97(2): 345-355.
Acta Anaesthesiologica Scandinavica
Effect of propofol on pathologic time-course and apoptosis after cerebral ischemia-reperfusion injury
Chen, L; Xue, Z; Jiang, H
Acta Anaesthesiologica Scandinavica, 52(3): 413-419.
Neurocritical Care
Therapy of intracranial hypertension in patients with fulminant hepatic failure
Raghavan, M; Marik, PE
Neurocritical Care, 4(2): 179-189.
European Journal of Pharmacology
Propofol: A review of its non-anaesthetic effects
Vasileiou, I; Xanthos, T; Koudouna, E; Perrea, D; Klonaris, C; Katsargyris, A; Papadimitriou, L
European Journal of Pharmacology, 605(): 1-8.
European Journal of Anaesthesiology
Effects of propofol and halothane on long-term potentiation in the rat hippocampus after transient cerebral ischaemia
Kakehata, J; Togashi, H; Yamaguchi, T; Morimoto, Y; Yoshioka, M
European Journal of Anaesthesiology, 24(): 1021-1027.
Journal of International Medical Research
High-dose Propofol Triggers Short-term Neuroprotection and Long-term Neurodegeneration in Primary Neuronal Cultures from Rat Embryos
Berns, M; Seeberg, L; Schmidt, M; Kerner, T
Journal of International Medical Research, 37(3): 680-688.

Current Pharmaceutical Design
Propofol: Therapeutic indications and side-effects
Marik, PE
Current Pharmaceutical Design, 10(): 3639-3649.

Journal of Cardiothoracic and Vascular Anesthesia
High-Dose Propofol Reduces S-100 beta Protein and Neuron-Specific Enolase Levels in Patients Undergoing Cardiac Surgery
Ma, G; Chen, JH; Meng, XK; Deng, LQ; Gao, YH; Meng, JH
Journal of Cardiothoracic and Vascular Anesthesia, 27(3): 510-515.
Neurological Sciences
Propofol exerts hippocampal neuron protective effects via up-regulation of metallothionein-3
He, JG; Huang, CS; Jiang, J; Lv, LH
Neurological Sciences, 34(2): 165-171.
Effect of propofol on hypoxia re-oxygenation induced neuronal cell damage in vitro
Huang, Y; Zitta, K; Bein, B; Scholz, J; Steinfath, M; Albrecht, M
Anaesthesia, 68(1): 31-39.
Neuroprotective Effects of Propofol in Models of Cerebral Ischemia: Inhibition of Mitochondrial Swelling as a Possible Mechanism
Adembri, C; Venturi, L; Tani, A; Chiarugi, A; Gramigni, E; Cozzi, A; Pancani, T; De Gaudio, RA; Pellegrini-Giampietro, DE
Anesthesiology, 104(1): 80-89.

PDF (1652)
Sevoflurane Protects Rat Mixed Cerebrocortical Neuronal–Glial Cell Cultures against Transient Oxygen–Glucose Deprivation: Involvement of Glutamate Uptake and Reactive Oxygen Species
Canas, PT; Velly, LJ; Labrande, CN; Guillet, BA; Sautou-Miranda, V; Masmejean, FM; Nieoullon, AL; Gouin, FM; Bruder, NJ; Pisano, PS
Anesthesiology, 105(5): 990-998.

PDF (822)
Journal of Neurosurgical Anesthesiology
The Direct Effects of Propofol on Pial Microvessels in Rabbits
Shibuya, K; Ishiyama, T; Ichikawa, M; Sato, H; Okuyama, K; Sessler, DI; Matsukawa, T
Journal of Neurosurgical Anesthesiology, 21(1): 40-46.
PDF (181) | CrossRef
Journal of Neurosurgical Anesthesiology
Glutamate-induced c-Jun Expression in Neuronal PC12 Cells: The Effects of Ketamine and Propofol
Wang, L; Jing, W; Hang, YN
Journal of Neurosurgical Anesthesiology, 20(2): 124-130.
PDF (229) | CrossRef
Journal of Neurosurgical Anesthesiology
Quantitative Evaluation of the Neuroprotective Effects of Thiopental Sodium, Propofol, and Halothane on Brain Ischemia in the Gerbil: Effects of the Anesthetics on Ischemic Depolarization and Extracellular Glutamate Concentration
Kobayashi, M; Takeda, Y; Taninishi, H; Takata, K; Aoe, H; Morita, K
Journal of Neurosurgical Anesthesiology, 19(3): 171-178.
PDF (354) | CrossRef
Back to Top | Article Outline

© 2003 American Society of Anesthesiologists, Inc.

Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.

Article Tools